US › Healthcare

Sol Gel Technologies Ltd (SLGL)

US · Healthcare · Biotechnology

$61.01-3.17%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$591,000

Revenue YoY

-96.6%

Net profit

$-3.7M

Profit YoY

-131.7%

EPS

$-1.13

EPS estimate

$-2.31

Net margin

-622.8%

EPS came in at -1.13 against a street estimate of -2.31 — a beat of 51.1%.

Key statistics

Market cap

$223.8M

Forward P/E

9.3

P/B

4.61

Book value

$14.69

EPS (TTM)

$-5.61

52-week high

$97.97

52-week low

$28.81

50-day MA

$69.04

200-day MA

$74.03

Beta

1.15

Analyst view

Analysts rate Sol Gel Technologies Ltd a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $152.50.

Shareholding

Insiders

59.73%

Institutions

43.84%

Largest institutional holders

Fund	Stake
Opaleye Management Inc	15.27%
Great Point Partners LLC	8.38%
Phoenix Financial Ltd	4.46%
Trails Edge Capital Partners, LP	4.26%
Affinity Asset Advisors, LLC	2.59%
Squadron Capital Management LLC	1.59%
Citadel Advisors Llc	0.99%
Gilder Gagnon Howe & CO LLC	0.69%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sol Gel Technologies Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.